This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

OncoSec Medical Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	9.7yrs

Son yönetim güncellemeleri

Recent updates

CEO

OncoSec Medical CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Heller	Member of Scientific Advisory Board	12.4yrs	Veri yok	Veri yok
Walter John Urba	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Iacob Mathiesen	Member of Scientific Advisory Board	12.4yrs	Veri yok	Veri yok
Pamela Munster	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Axel Hauschild	Member of Clinical Advisory Board	10.3yrs	Veri yok	Veri yok
Soldano Ferrone	Member of Scientific Advisory Board	9yrs	Veri yok	Veri yok
Alain Algazi	Member of Clinical Advisory Board	4.8yrs	Veri yok	Veri yok
Julie Shin	Board Observer	4.5yrs	Veri yok	Veri yok
Robert H.I. Andtbacka	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Georgina Long	Member of Clinical Advisory Board	no data	Veri yok	Veri yok

9.7yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: ONMA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2023/06/28 02:47
Gün Sonu Hisse Fiyatı	2023/06/28 00:00
Kazançlar	2023/01/31
Yıllık Kazançlar	2022/07/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

OncoSec Medical Incorporated 11 Bu analistlerden , raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
Thomas Shrader	BTIG
Raghuram Selvaraju	H.C. Wainwright & Co.

This company is no longer active

OncoSec Medical Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer

High number of new directors

OncoSec Medical Incorporated Elects Robert H. Arch as Non-Independent Director of the Board

OncoSec Medical Incorporated Elects Stephany Foster as an Independent Director

OncoSec Medical Incorporated Appoints Joon Kim to the Audit Committee

OncoSec Medical Incorporated, Annual General Meeting, Nov 23, 2022

Recent updates

OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million.

Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program

High number of new directors

OncoSec Medical Incorporated Receives Notice from the Nasdaq Stock Market LLC

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated Presents Encouraging Early Data with TAVO™-EP combined with Nivolumab (Opdivo®) in Neoadjuvant Melanoma

Oncosec Medical Incorporated Announces Positive Clinical Data of the Keynote-695 Trial Assessing Tavo-Ep in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to Anti-Pd-1 Treatment

OncoSec Medical Incorporated Elects Robert H. Arch as Non-Independent Director of the Board

OncoSec Medical Incorporated Elects Stephany Foster as an Independent Director

OncoSec Medical Incorporated Announces Workforce Reduction

OncoSec Medical Incorporated Appoints Joon Kim to the Audit Committee

OncoSec Medical Incorporated, Annual General Meeting, Nov 23, 2022

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated Appoints Robert H. Arch as Chief Executive Officer

Less than half of directors are independent

OncoSec Medical Incorporated, Annual General Meeting, Jul 12, 2022

OncoSec Medical Incorporated Announces Appointment of George Chi as Chief Financial Officer

Oncosec Medical Receives Notice from the Nasdaq Stock Market

Less than half of directors are independent

Interim CEO & COO Brian Leuthner has left the company

Forecast to breakeven in 2024

President, CEO & Director Daniel O'Connor has left the company

OncoSec Medical Incorporated, Annual General Meeting, Apr 29, 2021

OncoSec Medical Incorporated Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, Tavo™, in Triple Negative Breast Cancer

OncoSec Medical Incorporated Appoints Bridget O'keeffe as Vice President of Clinical Development

OncoSec Medical Incorporated Announces Management Appointments

New 90-day high: €6.10

OncoSec Announces First Subjects Dosed in Phase 1 Trial of Corvax12, Oncosec's Covid-19 Vaccine Candidate Combining Interleukin-12 (Il-12) with an Enhanced Sars-Cov-2 Spike Protein

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $42.026498 million.

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

New 90-day high: €5.55

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

New 90-day high: €5.05

OncoSec Medical Incorporated Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO and its Gene Electrotransfer Technology

OncoSec Medical Incorporated Announces Exclusive License Agreement for Cliniporator Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics

OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020

New 90-day high: €4.04

OncoSec Medical Incorporated to Present Positive Interim Data from Keynote-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19

OncoSec Medical Incorporated Announces Stepping Down of Kellie Malloy Foerter as Chief Operating Officer

OncoSec Medical Incorporated Announces Appointment of Sandra Aung as Senior Vice President, Chief Clinical Development Officer

OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO and Its Gene Delivery Platform

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $14.977914 million.

New 90-day high - €3.12

CEO